Information Provided By: 
Fly News Breaks for September 23, 2016
SRPT
Sep 23, 2016 | 15:21 EDT
Piper Jaffray analyst Edward Tenthoff says Sarepta Therapeutics has a strengthened balance sheet after issuing 5.02M shares at a price of $59.75. Further, for its Exondys51 approval, Sarepta gained a Rare Priority Review Voucher that could be sold to further pad the company's cash position, Tenthoff tells investors in an intraday research note. He reiterates an Overweight rating on the shares with a $64 price target. The stock is down 5% to $57.74 in late afternoon trading.
News For SRPT From the Last 2 Days
There are no results for your query SRPT
